Application of in vivo animal models to characterize the pharmacokinetic and pharmacodynamic properties of drug candidates in discovery settings

Combinatorial Chemistry and High Throughput Screening

Volumn 13, Issue 2, 2010, Pages 207-218

  Amore, Benny M ^a   Gibbs, John P ^a   Emery, Maurice G ^a  

^a AMGEN INC   (United States)

Author keywords

Drug discovery; In vivo; Pharmacodynamics; Pharmacokinetics

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; BENZODIAZEPINE; BORNEOL; CEPHALOSPORIN; CYTOTOXIC AGENT; DECAPENTAPLEGIC PROTEIN; ERYTHROPOIETIN; GAMMA SECRETASE INHIBITOR; LEVODOPA; METFORMIN; OPIATE; PENICILLIN G; PROTEIN TYROSINE KINASE INHIBITOR; TERPENOID DERIVATIVE; VASCULOTROPIN;

AREA UNDER THE CURVE; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DELIVERY SYSTEM; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG EFFECT; DRUG EFFICACY; DRUG ELIMINATION; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TOXICITY; HIGH THROUGHPUT SCREENING; IN VITRO STUDY; IN VIVO STUDY; LIPOPHILICITY; NONHUMAN; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; REVIEW;

ANIMALS; DRUG DISCOVERY; HUMANS; MODELS, ANIMAL; PHARMACOKINETICS;

ANIMALIA;

EID: 77949841570     PISSN: 13862073     EISSN: None     Source Type: Journal    
DOI: 10.2174/138620710790596808     Document Type: Review

References (77)

1. Lipinski, C.A.; Lombardo, F.; Dominy, B.W.; Feeney, P.J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev., 1997, 23, 3-25.
2. Kramer, J.A.; Sagartz, J.E.; Morris, D.L. The application of discovery toxicology and pathology towards the design of safer pharmaceutical lead candidates. Nat. Rev. Drug Discov., 2007, 6, 636-649.
3. Reinhart, G.A.; Fryer, R.M.; Osinski, M.A.; Polakowski, J.S.; Cox, B.F.; Gintant, G.A. Predictive, non-GLP models of secondary pharmacodynamics: Putting the best compounds forward. Curr. Opin. Chem. Biol., 2005, 9, 392-399.
4. Lin, J.H. Role of pharmacokinetics in the discovery and development of indinavir. Adv. Drug Deliv. Rev., 1999, 39, 33-49.
5. Baxter, A.; Cooper, A.; Kinchin, E.; Moakes, K.; Unitt, J.; Wallace, A. Hit-to-lead studies: The discovery of potent, orally bioavailable thiazolopyrimidine CXCR2 receptor antagonists. Bioorg. Med. Chem. Lett., 2006, 16, 960-963.
6. Leeson, P.D.; Springthorpe, B. The influence of drug-like concepts on decision-making in medicinal chemistry. Nat. Rev. Drug Discov., 2007, 6, 881-890.
7. Muller, K.; Faeh, C.; Diederich, F. Fluorine in pharmaceuticals: Looking beyond intuition. Science, 2007, 317, 1881-1886.
8. L-adrenoceptor antagonists. Drug Metab. Dispos., 2007, 35, 1435-1445.
9. Anderson, N.; Borlak, J. Drug-induced phospholipidosis. FEBS Lett., 2006, 580, 5533-5540.
10. Backes, J.M.; Venero, C.V.; Gibson, C.A.; Ruisinger, J.F.; Howard, P.A.; Thompson, P.D.; Moriarty, P.M. Effectiveness and tolerability of every-other-day rosuvastatin dosing in patients with prior statin intolerance. Ann. Pharmacother., 2008, 42, 341-346.
11. Smyth, A.; Tan, K.H.; Hyman-Taylor, P.; Mulheran, M.; Lewis, S.; Stableforth, D.; Prof Knox, A. Once versus three-times daily regimens of tobramycin treatment for pulmonary exacerbations of cystic fibrosis-the TOPIC study: A randomized controlled trial. Lancet, 2005, 365, 573-578.
12. Ibrahim, K.H.; Gunderson, B.W.; Hermsen, E.D.; Hovde, L.B.; Rotschafer, J.C. Pharmacodynamics of pulse dosing versus standard dosing: In vitro metronidazole activity against bacteroides fragilis and bacteroides thetaiotaomicron. Antimicrob. Agents Chemother., 2004, 48, 4195-4199.
13. Herman, G.A.; Stevens, C.; Van Dyck, K.; Bergman, A.; Yi, B.; De Smet, M.; Snyder, K.; Hilliard, D.; Tanen, M.; Tanaka, W.; Wang, A.Q.; Zeng, W.; Musson, D.; Winchell, G.; Davies, M.J.; Ramael, S.; Gottesdiener, K.M.; Wagner, J.A. Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: Results from two randomized, double-blind, placebo-controlled studies with single oral doses. Clin. Pharmacol. Ther., 2005, 78, 675-688.
14. He, Y.L.; Serra, D.; Wang, Y.; Campestrini, J.; Riviere, G.J.; Deacon, C.F.; Holst, J.J.; Schwartz, S.; Nielsen, J.C.; Ligueros-Saylan, M. Pharmacokinetics and pharmacodynamics of vildagliptin in patients with type 2 diabetes mellitus. Clin. Pharmacokinet., 2007, 46, 577-588.
15. Karpel, J.P.; Busse, W.W.; Noonan, M.J.; Monahan, M.E.; Lutsky, B.; Staudinger, H. Effects of mometasone furoate given once daily in the evening on lung function and symptom control in persistent asthma. Ann. Pharmacother., 2005, 39, 1977-1983.
16. Sheiner, L.B.; Stanski, D.R.; Vozeh, S.; Miller, R.D.; Ham, J. Simultaneous modeling of pharmacokinetics and pharmacodynamics: Application to d-tubocurarine. Clin. Pharm. Ther., 1979, 25, 358-371.
17. Sharma, A.; Jusko, W. J. Characterization of four basic models of indirect pharmacodynamic responses. J. Pharmacokinet. Biopharm., 1996, 24, 611-635.
18. Jusko, W.J. Pharmacodynamics of chemotherapeutic effects: Dosetime-response relationships for phase-nonspecific agents. J. Pharm. Sci., 1971, 60, 892-895.
19. Simeoni, M.; Magni, P.; Cammia, C.; De Nicolao, G.; Croci, V.; Pesenti, E.; Germani, M.; Poggesi, I.; Rocchetti, M. Predictive pharmacokinetic- pharmacodynamic modeling of tumor growth kinetics in xenograft models after administration of anticancer agents. Cancer Res., 2004, 64, 1094-1101.
20. White, R.E.; Manitpisitkul, P. Pharmacokinetic theory of cassette dosing in drug discovery screening. Drug Metab. Dispos., 2001, 29, 957-966.
21. Smith, N.F.; Raynaud, F.I.; Workman, P. The application of cassette dosing for pharmacokinetic screening in small-molecule cancer drug discovery. Mol. Cancer Ther., 2007, 6, 428-440.
22. Manitpisitkul, P.; White, R. E. Whatever happened to cassette-dosing pharmacokinetics? Drug Discov. Today, 2004, 9, 652-658.
23. He, K.; Qian, M.; Wong, H.; Bai, S.A.; He, B.; Brogdon, B.; Grace, J.E.; Xin, B.; Wu, J.; Ren, S.X.; Zeng, H.; Deng, Y.; Graden, D.M.; Olah, T.V.; Unger, S.E.; Luettgen, J.M.; Knabb, R.M.; Pinto, D. J.; Lam, P. Y.; Duan, J.; Wexler, R.R.; Decicco, C.P.; Christ, D.D.; Grossman, S.J. N-in-1 dosing pharmacokinetics in drug discovery: Experience, theoretical and practical considerations. J. Pharm. Sci., 2008, 97, 2568-2580.
24. Ito, K.; Iwatsubo, T.; Kanamitsu, S.; Ueda, K.; Suzuki, H.; Sugiyama, Y. Prediction of pharmacokinetic alterations caused by drug-drug interactions: Metabolic interaction in the liver. Pharmacol. Rev., 1998, 50, 387-412.
25. Rowland, M.; Matin, S.B. Kinetics of drug-drug interactions. J. Pharmacokinet. Biopharm., 1973, 1, 553-567.
26. Smith, N.F.; Hayes, A.; Nutley, B.P.; Raynaud, F.I.; Workman, P. Evaluation of the cassette dosing approach for assessing the pharmacokinetics of geldanamycin analogues in mice. Cancer Chemother. Pharmacol., 2004, 54, 475-486.
27. Olah, T.V.; McLoughlin, D.A.; Gilbert, J.D. The simultaneous determination of mixtures of drug candidates by liquid chromatography/ atmospheric pressure chemical ionization mass spectrometry as an in vivo drug screening procedure. Rapid Commun. Mass Spectrom, 1997, 11, 17-23.
28. Hsieh, Y.; Bryant, M.S.; Brisson, J.M.; Ng, K.; Korfmacher, W.A. Direct cocktail analysis of drug discovery compounds in pooled plasma samples using liquid chromatography-tandem mass spectrometry. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci., 2002, 767, 353-362.
29. Kuo, B.S.; Van Noord, T.; Feng, M.R.; Wright, D.S. Sample pooling to expedite bioanalysis and pharmacokinetic research. J. Pharm. Biomed. Anal., 1998, 16, 837-846.
30. Atherton, J.P.; Van Noord, T.J.; Kuo, B.S. Sample pooling to enhance throughput of brain penetration study. J. Pharm. Biomed. Anal., 1999, 20, 39-47.
31. Cox, K.A.; White, R.E.; Korfmacher, W.A. Rapid determination of pharmacokinetic properties of new chemical entities: In vivo approaches. Comb. Chem. High Throughput Screen., 2002, 5, 29-37.
32. Hop, C.E.; Wang, Z.; Chen, Q.; Kwei, G. Plasma-pooling methods to increase throughput for in vivo pharmacokinetic screening. J. Pharm. Sci., 1998, 87, 901-903.
33. Cheung, B.W.; Cartier, L.L.; Russlie, H.Q.; Sawchuk, R.J. The application of sample pooling methods for determining AUC, AUMC and mean residence times in pharmacokinetic studies. Fundam. Clin. Pharmacol., 2005, 19, 347-354.
34. Li, Q.; Kozar, M.P.; Shearer, T.W.; Xie, L.H.; Lin, A.J.; Smith, K.S.; Si, Y.; Anova, L.; Zhang, J.; Milhous, W. K.; Skillman, D.R. Pharmacokinetics, safety, and hydrolysis of oral pyrrolquinazolinediamines administered in single and multiple doses in rats. Antimicrob. Agents Chemother., 2007, 51, 2898-2904.
35. Beier, H.; Kaiser, K.; Langhans, M.; Malmendier, K.; Sluijsmans, I.; Weiher, J. Peritoneal microdialysis in freely moving rodents: An alternative to blood sampling for pharmacokinetic studies in the rat and the mouse. Eur. J. Pharm. Sci., 2007, 30, 75-83.
36. Korfmacher, W.A.; Cox, K.A.; Ng, K.J.; Veals, J.; Hsieh, Y.; Wainhaus, S.; Broske, L.; Prelusky, D.; Nomeir, A.; White, R.E. Cassette-accelerated rapid rat screen: a systematic procedure for the dosing and liquid chromatography/atmospheric pressure ionization tandem mass spectrometric analysis of new chemical entities as part of new drug discovery. Rapid Commun. Mass Spectrom., 2001, 15, 335-340.
37. Mei, H.; Korfmacher, W.; Morrison, R. Rapid in vivo oral screening in rats: Reliability, acceptance criteria, and filtering efficiency. AAPS J., 2006, 8, E493-500.
38. Han, H. K.; Sadagopan, N.; Reichard, G. A.; Yapa, U.; Zhu, T.; Hubbel, A.; Johnson, K.; Brodfuehrer, J. An efficient approach for the rapid assessment of oral rat exposures for new chemical entities in drug discovery. J. Pharm. Sci., 2006, 95, 1684-1692.
39. van Warmerdam, L.J.; ten Bokkel Huinink, W.W.; Maes, R.A.; Beijnen, J.H. Limited-sampling models for anticancer agents. J. Cancer Res. Clin. Oncol., 1994, 120, 427-439.
40. Jodrell, D.I.; Murray, L.S.; Hawtof, J.; Graham, M.A.; Egorin, M.J.A comparison of methods for limited-sampling strategy design using data from a phase 1 trial of the anthrapyrazole DuP-941. Cancer Chemother. Pharmacol., 1996, 37, 356-362.
41. Mistry, M.; Houston, J.B. Quantitation of extrahepatic metabolism. Drug Metab. Dispos., 1985, 13, 740-4.
42. Letendre, L.; Scott, M.; Dobson, G.; Hidalgo, I.; Aungst, B. Evaluating barriers to bioavailability in vivo: Validation of a technique for separately assessing gastrointestinal absorption and hepatic extraction. Pharm. Res., 2004, 21, 1457-1462.
43. Hoglen, N.C.; Chen, L.S.; Fisher, C.D.; Hirakawa, B.P.; Groessl, T.; Contreras, P.C. Characterization of IDN-6556 (3-{2-(2-tertbutyl- phenylaminooxalyl)-amino]-propionylamino} -4-oxo-5-(2,3,5,6-tetrafluoro-phenoxy) -pentanoic acid): A liver-targeted caspase inhibitor. J. Pharmacol. Exp. Ther., 2004, 309, 634-640.
44. Ortiz de Montellano, P.R.; Mathews, J.M.; Langry, K.C. Autocatalytic inactivation of cytochrome P-450 and chloroperoxidase by 1-aminobenzotriazole and other aryne precusors. Tetrahedron, 1984, 40, 511-519.
45. Balani, S.K.; Zhu, T.; Yang, T.J.; Liu, Z.; He, B.; Lee, F.W. Effective dosing regimen of 1-aminobenzotriazole for inhibition of antipyrine clearance in rats, dogs, and monkeys. Drug Metab. Dispos., 2002, 30, 1059-1062.
46. Balani, S.K.; Li, P.; Nguyen, J.; Cardoza, K.; Zeng, H.; Mu, D.X.; Wu, J.T.; Gan, L.S.; Lee, F.W. Effective dosing regimen of 1-aminobenzotriazole for inhibition of antipyrine clearance in guinea pigs and mice using serial sampling. Drug Metab. Dispos., 2004, 32, 1092-1095.
47. Caldwell, G.W.; Ritchie, D.M.; Masucci, J.A.; Hageman, W.; Cotto, C.; Hall, J.; Hasting, B.; Jones, W. The use of the suicide CYP P450 inhibitor ABT for distinguishing absorption and metabolism processes in in vivo pharmacokinetic screens. Eur. J. Drug Metab. Pharmacokinet., 2005, 30, 75-83.
48. Strelevitz, T.J.; Foti, R.S.; Fisher, M.B. In vivo use of the P450 inactivator 1-aminobenzotriazole in the rat: Varied dose route to elucidate gut and liver contributions to first-pass and systemic clearance. J. Pharm. Sci., 2006, 95, 1334-1341.
49. Lin, J.H.; Chen, I.W.; Chiba, M.; Nishime, J.A.; Deluna, F.A. Route-dependent nonlinear pharmacokinetics of a novel HIV protease inhibitor: Involvement of enzyme inactivation. Drug Metab. Dispos., 2000, 28, 460-466.
50. Williams, D. P.; Antoine, D. J.; Butler, P. J.; Jones, R.; Randle, L.; Payne, A.; Howard, M.; Gardner, I.; Blagg, J.; Park, B. K. The metabolism and toxicity of furosemide in the wistar rat and CD-1 mouse: A chemical and biochemical definition of the toxicophore. J. Pharmacol. Exp. Ther., 2007, 322, 1208-1220.
51. Watkins, J.B.; Klaassen, C.D. Chemically-induced alteration of UPD-glucuronic acid concentration in rat liver. Drug Metab. Dispos., 1983, 11, 37-40.
52. Lin, L.A.; Shangari, N.; Chan, T.S.; Remirez, D.; O'Brien, P.J. Herbal monoterpene alcohols inhibit propofol metabolism and prolong anesthesia time. Life Sci, 2006, 79, 21-29.
53. Li, C.; Grillo, M.P.; Benet, L. Z. In vivo mechanistic studies on the metabolic activation of 2-phenylpropionic acid in rat. J. Pharmacol. Exp. Ther., 2003, 305, 250-256.
54. Ward, K.W.; Stelman, G.J.; Morgan, J.A.; Zeigler, K.S.; Azzarano, L.M.; Kehler, J.R.; McSurdy-Freed, J.E.; Proksch, J.W.; Smith, B.R. Development of an in vivo preclinical screen model to estimate absorption and first-pass hepatic extraction of xenobiotics. II. Use of ketoconazole to identify P-glycoprotein/CYP3A-limited bioavailability in the monkey. Drug Metab. Dispos., 2004, 32, 172-177.
55. Lau, Y.Y.; Okochi, H.; Huang, Y.; Benet, L.Z. Multiple transporters affect the disposition of atorvastatin and its two active hydroxy metabolites: Application of in vitro and ex situ systems. J. Pharmacol. Exp. Ther., 2006, 316, 762-771.
56. Dingemanse, J.; Appel-Dingemanse, S. Integrated pharmacokinetics and pharmacodynamics in drug development. Clin. Pharmacokinet., 2007, 46, 713-737.
57. Lin, J. H. Tissue distribution and pharmacodynamics: A complicated relationship. Curr. Drug Metab., 2006, 7, 39-65.
58. Reichel, A. The role of blood-brain barrier studies in the pharmaceutical industry. Curr. Drug Metab., 2006, 7, 183-203.
59. Raje, S.; Cornish, J.; Newman, A.H.; Cao, J.; Katz, J.L.; Eddington, N.D. Pharmacodynamic assessment of the benztropine analogues AHN-1055 and AHN-2005 using intracerebral microdialysis to evaluate brain dopamine levels and pharmacokinetic/ pharmacodynamic modeling. Pharm. Res., 2005, 22, 603-612.
60. u and correlation of in vitro, preclinical, and clinical data. J. Pharmacol. Exp. Ther., 2007, 323, 346-355.
61. Kalvass, J.C.; Maurer, T.S. Influence of nonspecific brain and plasma binding on CNS exposure: implications for rational drug discovery. Biopharm. Drug Dispos., 2002, 23, 327-338.
62. Summerfield, S. G.; Stevens, A. J.; Cutler, L.; del Carmen Osuna, M.; Hammond, B.; Tang, S.P.; Hersey, A.; Spalding, D. J.; Jeffrey, P. Improving the in vitro prediction of in vivo central Nervous system penetration: Integrating permeability, P-glycoprotein efflux, and free fractions in blood and brain. J. Pharmacol. Exp. Ther., 2006, 316, 1282-1290.
63. Summerfield, S.G.; Read, K.; Begley, D.J.; Obradovic, T.; Hidalgo, I.J.; Coggon, S.; Lewis, A.V.; Porter, R. A.; Jeffrey, P. Central nervous system drug disposition: The relationship between in situ brain permeability and brain free fraction. J. Pharmacol. Exp. Ther., 2007, 322, 205-213.
64. Goldstein, M.E.; Cao, Y.; Fiedler, T.; Toyn, J.; Iben, L.; Barten, D.M.; Pierdomenico, M.; Corsa, J.; Prasad, C.V.; Olson, R.E.; Li, Y.W.; Zaczek, R.; Albright, C. F. Ex vivo occupancy of γ-secretase inhibitors correlates with brain β-amyloid peptide reduction in Tg2576 mice. J. Pharmacol. Exp. Ther., 2007, 323, 102-108.
65. Hay, M.P.; Hicks, K.O.; Pruijn, F.B.; Pchalek, K.; Siim, B.G.; Wilson, W.R.; Denny, W.A. Pharmacokinetic/pharmacodynamic model-guided identification of hypoxia-selective 1,2,4-benzotriazine 1,4-dioxides with antitumor activity: The role of extravascular transport. J. Med. Chem., 2007, 50, 6392-6404.
66. Hendrikse, N. H.; de Vries, E.G.; Eriks-Fluks, L.; van der Graaf, W.T.; Hospers, G.A.; Willemsen, A.T.; Vaalburg, W.; Franssen, E. J. A new in vivo method to study P-glycoprotein transport in tumors and the blood-brain barrier. Cancer Res., 1999, 59, 2411-2416.
67. Katsube, T.; Yamano, Y.; Yano, Y. Pharmacokineticpharmacodynamic modeling and simulation for in vivo bactericidal effect in murine infection model. J. Pharm. Sci., 2008, 97, 1606-1614.
68. Rocchetti, M.; Simeoni, M.; Pesenti, E.; De Nicolao, G.; Poggesi, I. Predicting the active doses in humans from animal studies: A novel approach in oncology Eur. J. Cancer, 2007, 43, 1862-1868.
69. Meno-Tetang, G. M.; Lowe, P. J. On the prediction of the human response: A recycled mechanistic pharmacokinetic/pharmacodynamic approach. Basic Clin. Pharmacol. Toxicol., 2005, 96, 182-192.
70. Mordenti, J.; Thomsen, K.; Licko, V.; Chen, H.; Meng, Y.G.; Ferrara, N. Efficacy and concentration-response of murine anti-VEGF monoclonal antibody in tumor-bearing mice and extrapolation to humans. Toxicol. Pathol., 1999, 27, 14-21.
71. Lee, L.; Sharma, S.; Morgan, B.; Allegrini, P.; Schnell, C.; Brueggen, J.; Cozens, R.; Horsfield, M.; Guenther, C.; Steward, W.P.; Drevs, J.; Lebwohl, D.; Wood, J.; McSheehy, P.M. Biomarkers for assessment of pharmacologic activity for a vascular endothelial growth factor (VEGF) receptor inhibitor, PTK787/ZK 222584 (PTK/ZK): translation of biological activity in a mouse melanoma metastasis model to phase I studies in patients with advanced colorectal cancer with liver metastases. Cancer Chemother. Pharmacol., 2006, 57, 761-771.
72. Woo, S.; Krzyzanski, W.; Jusko, W.J. Pharmacokinetic and pharmacodynamic modeling of recombinant human erythropoietin after intravenous and subcutaneous administration in rats. J. Pharmacol. Exp. Ther., 2006, 319, 1297-1306.
73. Kim, D.; Wang, L.; Beconi, M.; Eiermann, G.J.; Fisher, M.H.; He, H.; Hickey, G. J.; Kowalchick, J. E.; Leiting, B.; Lyons, K.; Marsilio, F.; McCann, M.E.; Patel, R.A.; Petrov, A.; Scapin, G.; Patel, S.B.; Roy, R.S.; Wu, J.K.; Wyvratt, M.J.; Zhang, B.B.; Zhu, L.; Thornberry, N. A.; Weber, A. E. (2R)-4-Oxo-4-[3-(Trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4, 3-a]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine: A potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. J. Med. Chem., 2005, 48, 141-151.
74. Cox, E.H.; Kerbusch, T.; Van der Graaf, P.H.; Danhof, M. Pharmacokinetic-pharmacodynamic modeling of the electroencephalogram effect of synthetic opioids in the rat: Correlation with the interaction at the mu-opioid receptor. J. Pharmacol. Exp. Ther., 1998, 284, 1095-1103.
75. 2-[(2S)-2-(3,5-Difluorophenyl)-2-hydroxyethanoyl] -N1-[(7S)-5-methyl-6-oxo-6,7-dihydro-5H-dibenzo[b,d] azepin-7-yl]-L-alaninamide (LY-411575). J. Pharmacol. Exp. Ther., 2004, 309, 49-55.
76. Beckman, N.; Kneuer, R.; Gremlich, H.U.; Karmouty-Quintana, H.; Ble, F. X.; Muller, M. In vivo mouse imaging and spectroscopy in drug discovery. NMR Biomed., 2007, 20, 154-185.
77. Craig, W. A. Pharmacokinetic/pharmacodynamic parameters: Rationale for antibacterial dosing of mice and men. Clin. Infect. Dis., 1998, 26, 1-12.